Diabetes continues to be a significant global health concern, with the Western Pacific region reporting the highest number of diabetes-related deaths in 2024, with around 1.2 million. This stark figure underscores the urgent need for improved diabetes prevention and management strategies worldwide. North America and the Caribbean followed with an estimated 526,000 deaths, while Africa is had the lowest number at 216,000. Regional disparities and global impact The prevalence of diabetes varies significantly across regions, reflecting differences in healthcare systems, lifestyle factors, and genetic predispositions. In the United States, the death rate from diabetes mellitus was 22.4 per 100,000 people in 2023, with 8.4 percent of the adult population living with the condition. Canada has seen a slight decrease in its diabetes-related death rate, falling from 21.8 per 100,000 in 2000 to 18.1 per 100,000 in 2023. These figures highlight the ongoing challenges in managing diabetes, even in countries with advanced healthcare systems. European landscape and global context Within Europe, Germany reported the highest number of diabetes-related deaths in 2024, with nearly 63,000 fatalities among adults aged 20 to 79 years. Italy followed closely with around 62,400 deaths. However, Czechia reported the highest mortality rates in Europe as of 2022, with 43.4 diabetes deaths per 100,000 population overall. On a global scale, diabetes remains a major health concern, with 19 percent of adults worldwide identifying it as one of the biggest health problems in their country.

The graph displays the number of diabetes-related deaths in the United States from 1999 to 2023. The x-axis represents the years, shown as full four-digit numbers from 1999 to 2023, while the y-axis shows the total number of annual deaths attributed to diabetes. Over this period, the number of deaths ranged from a low of 68,399 in 1999 to a peak of 103,000 in 2021. A sharp rise in diabetes deaths occurred between 2019 and 2021, followed by a gradual decline in the subsequent years. The graph highlights year-to-year changes in diabetes mortality rates.

In 2023, there were **** deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost ** deaths per 100,000 people in the early 2000s, and about ** deaths in 1980. Prevalence of diabetes In 2022, around *** percent of the adult population in the U.S. had diabetes. In total, around ** million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

Diabetes Mellitus death rates by county, all races (includes Hispanic/Latino), all sexes, all ages, 2019-2023. Death data were provided by the National Vital Statistics System. Death rates (deaths per 100,000 population per year) are age-adjusted to the 2000 US standard population (20 age groups: <1, 1-4, 5-9, ... , 80-84, 85-89, 90+). Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by the National Cancer Institute. The US Population Data File is used for mortality data. The Average Annual Percent Change is based onthe APCs calculated by the Joinpoint Regression Program (Version 4.9.0.0). Due to data availability issues, the time period used in the calculation of the joinpoint regression model may differ for selected counties. Counties with a (3) after their name may have their joinpoint regresssion model calculated using a different time period due to data availability issues.

AH Provisional Diabetes Death Counts for 2020

  Description

Provisional death counts of diabetes, coronavirus disease 2019 (COVID-19) and other select causes of death, by month, sex, and age.

  Dataset Details

Publisher: Centers for Disease Control and Prevention Temporal Coverage: 2020-01-01/2020-12-31 Last Modified: 2025-04-21 Contact: National Center for Health Statistics (cdcinfo@cdc.gov)

  Source

Original data can be found at:… See the full description on the dataset page: https://huggingface.co/datasets/HHS-Official/ah-provisional-diabetes-death-counts-for-2020.

In 2019-2021, the rate of new cases of diagnosed diabetes per 1,000 population aged 18 to 44 years in the United States was ****** This statistic shows the rate of new cases of diabetes among U.S. adults in 2019-2021, sorted by age group.

In 2019-2021, the rate of new cases of diagnosed diabetes among non-Hispanic white adults in the United States was around five per 1,000 population. This statistic shows the rate of new cases of diabetes among U.S. adults in 2019-2021, by race/ethnicity.

In 2023, it was estimated that almost 21 percent of those aged 65 years and older in the United States had been diagnosed with diabetes. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had diabetes from 2019 to 2023.

Prolonging life is a global trend, and more medical expenditure is being spent on chronic diseases owing to population aging. Diseases commonly seen in middle-aged and elderly people, such as heart disease and diabetes, have slowed mortality improvement in recent years. Diabetes is a common chronic disease and comorbidity of many serious health conditions. The total estimated cost of diabetes in the United States was $327 billion in 2017. However, many people are unaware that diabetes is common, and at least 21.4% of adults do not know that they have diabetes. The number of diabetes-related deaths has been increasing, and diabetes was the 5th cause of death in Taiwan in 2019. In this study, we explore the trend and influence of diabetes in Taiwan and apply mortality models, such as the Lee-Carter and Age-Period-Cohort models, using data from Taiwan’s National Insurance to model the incidence and mortality rates of diabetes. We found that the Lee-Carter model provides fairly satisfactory estimates and that people with diabetes regularly taking diabetes medication have lower mortality rates. Moreover, we demonstrate how these results can be used to design diabetes related insurance products and prepare the insured to face the impact of incurring diabetes. In addition, we consider different criteria for judging whether people have diabetes (as there is no consensus on these criteria) and investigate the issue of moral hazard in designing diabetes insurance products.

In 2019-2021, the rate of new cases of diagnosed diabetes among men in the United States was 6.4 per 1,000 population. This statistic shows the rate of new cases of diabetes among U.S. adults in 2019-2021, by gender.

In 2024, 15.4 percent of U.S. adults with a family income below the federal poverty level (FPL) reported being diagnosed with diabetes. Meanwhile, only 8.5 percent of respondents with a family income of at least 200% of the federal poverty level had diabetes.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Chronic kidney disease (CKD) caused heavy burden globally. This study aimed to investigate the patterns and temporal variations in the burden of CKD in China, Japan, the United Kingdom (U.K.), and the United States (U.S.) from 1990 to 2019, and decompose the difference in CKD disease burden between 1990 and 2019 into demographic factors. From 1990 to 2019, although the age-standardized rate (ASR) of incidence remained stable in the four countries, and the ASR of mortality and disability-adjusted life years (DALY) have declined in four countries (except for the increase in U.S.), the number of CKD incidence, death, and DALY increased significantly. The average disease burden per case in U.S. has increased between 1990 and 2019, with an increasing proportion of death-related disease burden. For the CKD due to diabetes and hypertension, whose incidences accounted for < 25% of the total CKD, while it accounts for more than 70% of the deaths (except in U.K. with 54.14% in women and 51.75% in men). CKD due to diabetes and hypertension should be the focus of CKD prevention and control. Considering the high treatment costs of CKD and ESRD, it is urgent and necessary to transform CKD treatment into primary and secondary prevention.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 receptor a

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031. North America held the major market share of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031. Europe accounted for a share of over 30% of the global revenue with a market size of USD XX million. Asia Pacific held the market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031. Latin America market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031. Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031. The Injection segment held the highest Specific Antiviral Drugs for COVID-19 market revenue share in 2024. Market Dynamics of Specific Antiviral Drugs for COVID-19 Market Key Drivers for Specific Antiviral Drugs for COVID-19 Market Urgent need for effective treatments to Increase the Demand Globally The emergence of the COVID-19 pandemic has underscored an urgent necessity for efficacious treatments. In the United States, mortality rates surged by 19% from 2019 to 2020 following the pandemic's onset in March 2020 — marking the most significant spike in deaths in a century. This uptick translated to a staggering 19% rise (535,191) in deaths, from 2,854,838 to 3,390,029. With the virus persisting globally, there exists a critical market demand for pharmaceutical solutions capable of directly combating the virus, mitigating symptoms, and ameliorating disease severity. Rising prevalence of chronic diseases to Propel Market Growth Individuals with underlying chronic conditions, such as diabetes, hypertension, heart disease, or respiratory disorders, face an increased risk of severe complications if they contract COVID-19. According to the CDC, 90% of the nation’s $3.8 trillion per year healthcare costs are linked to individuals with chronic diseases and mental health conditions. In 2017, the total costs of diagnosed diabetes in the United States amounted to $327 billion, including $237 billion in direct medical costs and $90 billion in lost economic productivity. Cardiovascular disease, which accounts for one in three deaths in the United States, underscores the urgent need for effective treatments, including specific antiviral drugs, to mitigate the severity of COVID-19 symptoms and enhance outcomes for this vulnerable population. Restraint Factor for the Specific Antiviral Drugs for COVID-19 Market Stringent regulatory requirements and high cost of pharmaceutical development to Limit the Sales Stringent regulatory criteria and protracted approval processes may postpone the introduction of novel antiviral medications into the market. The thorough assessment of safety and efficacy data by regulatory bodies like the FDA can prolong the time required for market entry, influencing the accessibility of specific antiviral treatments. Moreover, the elevated expenses associated with pharmaceutical development, manufacturing, and distribution may lead to costly antiviral drugs, restricting access for populations in low-income countries or regions with insufficient healthcare infrastructure. Concerns regarding affordability could trigger pricing pressures and reimbursement obstacles, impacting the adoption and profitability of these medications. Impact of Covid-19 on the Specific Antiviral Drugs for COVID-19 Market The critical necessity for efficacious treatments against COVID-19 has sparked a heightened demand for targeted antiviral medications. Given the swift global dissemination of the virus and subsequent surges in infections, there is an urgent requirement for pharmaceutical solutions capable of directly combating the virus and mitigating associated symptoms. The pandemic has catalyzed unparalleled levels of investment and cooperation in research and development endeavors focused on discovering effective antiviral treatments for COVID-19. Pharmaceutical firms, academic entities, and governments across the globe have pri...

BackgroundThe consumption of processed meat causes negative impacts on health; however, this burden for the population living in developing countries is less explored. This study aimed to describe the burden of chronic noncommunicable diseases (NCDs) attributed to a diet rich in processed meat between 1990 and 2019 in Brazil and its federative units and the financial burden on the Unified Health System (SUS) in 2019.MethodsSecondary data from the Global Burden of Disease (GBD) and SUS Information Systems were used in this ecological study. The metrics to assess the burden of NCDs attributable to processed meat consumption were disability-adjusted life years (DALYs) and deaths. The age-standardized rates were presented per 100,000 inhabitants with 95% uncertainty intervals (95% UI). The cost of hospitalizations and outpatient procedures covered by SUS for the treatment of NCDs attributable to processed meat consumption was estimated using the population-attributable fraction. Both burdens were estimated for both sex and stratified by sex, specific cause, and federative units.ResultsThe age-standardized DALY rates attributable to a diet rich in processed meat increased between 1990 (75.31/100,000 [95% UI: 34.92–139.65]) and 2019 (79.35/100,000 [95% UI: 42.84–126.25]); while mortality rates remained stable between 1990 (2.64/100,000 [95% UI: 1.17–5.21) and 2019 (2.36/100,000 [95% UI: 1.22–4.09]). The cost of hospitalization and outpatient procedures in Brazil for NCDs attributable to the consumption of processed meat was approximately US$ 9,4 million, of which US$ 6,1 million was spent on ischemic heart disease, US$ 3,1 million on colorectal cancer, and US$ 200 thousand on type 2 diabetes mellitus.ConclusionThe NCD burden did not decrease during the years evaluated, while the financial burden was high in 2019, with higher treatment costs for ischemic heart disease. These results can guide political, economic, and health education interventions to advance the fight against NCDs.

The leading causes of death in the United States are, by far, cardiovascular diseases and cancer. However, the death rates from these diseases, as well as other leading causes of death, have decreased over the past few decades. The one major exception is deaths caused by Alzheimer’s disease, which have increased significantly. Cardiovascular disease deaths Although cardiovascular diseases are currently the leading cause of death in the United States, the death rate of these diseases has dropped significantly. In the year 1950, there were around *** deaths per 100,000 population due to cardiovascular diseases. In the year 2023, this number was ***** per 100,000 population. Risk factors for heart disease include smoking, poor diet, diabetes, obesity, stress, family history, and age. Alzheimer’s disease deaths While the death rates for cardiovascular disease, cancer, diabetes, and chronic lower respiratory diseases have all decreased, the death rate for Alzheimer’s disease has increased. In fact, from the year 2000 to 2022, the death rate from Alzheimer’s disease rose an astonishing *** percent. This increase is in part due to a growing aging population.

Between 2019 and 2022, more than **** million people in Ghana had type 2 diabetes. On the other hand, prediabetic patients were around *** million people. As of 2022, the average per capita expenditure on diabetes care amounted to **** Ghanaian cedis, some *** U.S. dollars.

In 2019, the leading causes of death worldwide were ischemic heart disease, stroke, and chronic obstructive pulmonary disease (COPD). That year, ischemic heart disease and stroke accounted for a combined ** percent of all deaths worldwide. Although the leading causes of death worldwide vary by region and country, heart disease is a consistent leading cause of death regardless of income, development, size, or location. Heart disease In 2019, around **** million people worldwide died from ischemic heart disease. In comparison, around **** million people died from lung cancer that year, while *** million died from diabetes. The countries with the highest rates of death due to heart attack and other ischemic heart diseases are Lithuania, Russia, and Slovakia. Although some risk factors for heart disease, such as age and genetics, are unmodifiable, the likelihood of developing heart disease can be greatly reduced through a healthy lifestyle. The biggest modifiable risk factors for heart disease include smoking, an unhealthy diet, being overweight, and a lack of exercise. In 2019, it was estimated that around *** million deaths worldwide due to ischemic heart disease could be attributed to smoking. The leading causes of death in the United States Just as it is the leading cause of death worldwide, heart disease is also the leading cause of death in the United States. In 2023, heart disease accounted for ** percent of all deaths in the United States. Cancer was the second leading cause of death in the U.S. that year, followed by accidents. As of 2023, the odds that a person in the United States will die from heart disease is * in *. However, rates of death due to heart disease have actually declined in the U.S. over the past couple decades. From 2000 to 2022, there was a *** percent decline in heart disease deaths. On the other hand, deaths from Alzheimer’s disease saw an increase of *** percent over this period. Alzheimer’s disease is currently the sixth leading cause of death in the United States, accounting for **** deaths per 100,000 population in 2023.

The number of deaths caused by heart disease has decreased in the United States from ***** per 100,000 population in 1990 to ***** deaths per 100,000 population in 2019. Nevertheless, heart disease is still the leading cause of death in the country, followed closely by cancer, which has a mortality rate of ***** per 100,000 people. Heart disease in the U.S.Diseases of the heart and blood vessels are often associated with atherosclerosis, which occurs when plaque builds up along arterial walls. This can limit the flow of blood and can lead to blood clots, a common cause of stroke or heart attacks. Other types of heart disease include arrhythmia (abnormal heart rhythms) and heart valve problems. Many of these diseases can be treated with medication, although many complications will still remain. One of the leading cholesterol lowering drugs in the United States, Crestor, generated around **** billion U.S. dollars of revenue in 2024. Risk Factors for heart disease There are many risk factors associated with the development of heart disease, including family history, ethnicity, and age. However, there are other factors that can be modified through lifestyle changes such as physical inactivity, smoking, and unhealthy diets. Obesity has also been commonly associated with risk factors like hypertension and diabetes type II. In the United States, some ** percent of white adults are currently obese.